Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
AMRI > SEC Filings for AMRI > Form 8-K on 12-Aug-2013All Recent SEC Filings

Show all filings for ALBANY MOLECULAR RESEARCH INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for ALBANY MOLECULAR RESEARCH INC


12-Aug-2013

Other Events


Item 8.01 Other Events.

Albany Molecular Research, Inc. ("AMRI") has been informed by its license partner, Bristol-Myers Squibb ("BMS"), of its decision to terminate development of BMS-820836, an investigational triple reuptake inhibitor in phase II clinical development for Treatment Resistant Depression (TRD). This decision is being announced today to the various clinical investigators who had enrolled patients in phase II studies. A third ongoing safety study is being discontinued. According to BMS, this decision was made based on the drug's failure to achieve the primary endpoint in two phase IIb studies - superiority over duloxetine (an SNRI) or escitalopram (an SSRI) in patients with TRD. AMRI has learned that BMS intends to share further data from the two phase IIb studies at an appropriate scientific forum and/or in a scientific publication at a future date. The 2005 License and Research Agreement between AMRI and BMS (the "License Agreement") has been a source of past revenue for AMRI, providing for payments for research services and milestones earned on specific compounds. This decision by BMS regarding BMS-820836 will have no impact on AMRI's financial guidance or forecasts, including, the Company's financial guidance for the third quarter and full year 2013 which was recently updated in the Company's press release and conference call on August 6, 2013. AMRI expects to have continued discussions with BMS regarding their plans for other development compounds and leads previously identified for potential development against TRD or other CNS indications.

This information is being furnished pursuant to Item 8.01 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

AMRI Forward-Looking Statement

Statements in this Form 8-K that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. The Company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the Company may not be able to predict and may not be within the Company's control. Factors that could cause such differences include, but are not limited to (a) the results of further clinical trials that are proceeding on other AMRI compounds licensed to BMS; and (b) the potential other applications for BMS-820836 and (c) the further discussions regarding the further activities of other AMRI compounds licensed to BMS and covered by the 2005 License and Research Agreement, as well as those factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission on March 18, 2013 and the Company's other SEC filings. The Company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.

  Add AMRI to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for AMRI - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.